Aeglea BioTherapeutics EBIT

The latest EBIT for AGLE is $-250M as of September 2026. That compares with $-85M in the prior-year period — down 194.9% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Aeglea BioTherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGLE's EBIT moved from $-85M to $-250M — a 194.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aeglea BioTherapeutics's operating scale or balance-sheet position.

Against Healthcare companies, AGLE currently prints $-250M for EBIT, while the sector average sits near $99B. That is roughly 100.3% below the sector mean. Large gaps often invite a closer look at Aeglea BioTherapeutics's growth, margins, and balance sheet.

A EBIT figure of $-250M for AGLE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting AGLE's EBIT ($-250M), review year-over-year change from $-85M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.